The 7 analysts offering 12-month price forecasts for Orchard Therapeutics PLC have a median target of 9.00, with a high estimate of 13.00 and a low estimate of 6.50. The median estimate represents a +625.81% increase from the last price of 1.24.
The current consensus among 8 polled investment analysts is to Buy stock in Orchard Therapeutics PLC. This rating has held steady since January, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.27
Reporting Date Mar 02
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.